Refractory Langerhans cell histiocytosis Recruiting Phase 2 Trials for X-396 (DB13104)

IndicationStatusPhase
DBCOND0022006 (Refractory Langerhans cell histiocytosis)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03213652Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Treatment
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening